ITCI

Intra-Cellular Therapies, Inc. (ITCI) | Rumor.io

Intra-Cellular Therapies

ITCI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)96%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ITCI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Dec 7

Intra-Cellular Therapies' research may be relevant to Parkinson's disease treatment due to its focus on intra-cellular explanations.
Parkinson's disease is thought to involve a complex interplay between mitochondria, lysosomes, and inflammation.
The disease may be composed of multiple subtypes, including those triggered by genetic mutations and those caused by chronic systemic inflammation.

Generated by AI

Sentiment

Of the messages about ITCI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	91.22% +1.4
Bearish	—	0%	0% 0	8.78% -1.4

Bullish· Jan 14

$ITCI has a strong track record of revenue growth, with $2 in revenue generated for every $1 in expense.
The company's stock price has experienced significant growth, increasing from around $10 to $132, with a market capitalization of $14.6 billion.
Intra-Cellular Therapies has a promising clinical pipeline, with a potential acquisition by a large pharma company, and a recommended buy price range of $125 to $140.

Bearish· Apr 16

The market may have been primed for Intra-Cellular Therapies' recent decline, with limited drop in price after news of a half-billion dollar offering.
Intra-Cellular Therapies' current valuation is still considered too high by some investors, with a potential target price of $75 or less for a profitable exit.
The risk-reward ratio for biotech stocks, including Intra-Cellular Therapies, is seen as unfavorable, with potential losses of 50-60% or more outweighing potential gains of 15% or less.

Generated by AI

Topics

Of the messages about ITCI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0.17%
Announcements	—	—	100%	98.31%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	1.52%

Earnings· Jan 26

Intra-Cellular Therapies, Inc. (ITCI) share price may have popped on FDA approval due to initial doubts.
ITCI's approval reason was not the only factor, as other companies with favorable adcoms (Amarin, EPZM) didn't see a price increase.
ITCI's stock price may be subject to volatility following FDA approval, as seen with other biotech companies.

Analysts· Aug 24

JMP Securities upgraded Intra-Cellular Therapies ($ITCI) to Outperform with a price target of $24.
Intra-Cellular Therapies ($ITCI) received a Buy rating reaffirmed at Cowen and Company.
JMP Securities raised their rating for Intra-Cellular Therapies ($ITCI) to Market Outperform with a price target of $24.

Announcements· Jan 14

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies for $132 per share in cash, valuing the company at approximately $14.6 billion.
The acquisition will expand Johnson & Johnson's neuroscience portfolio and leverage Intra-Cellular Therapies' pipeline drugs, including Caplyta.
The deal is expected to close in the second quarter of 2025, with Intra-Cellular Therapies' stock soaring 34.07% to $127.19 on the news.

Technical Analysis· Dec 23

$ITCI has bounced back to $28.55 after pulling back to $25.00, with a significant increase in volume.
The stock is showing strong technical signals, including a bounce off the 200-day simple moving average and a possible break of the 20-day moving average.
Key levels to watch include $25, $28.75, and $30, with a potential retest of today's highs if the stock continues to rally.

Generated by AI

Community

Of the messages about ITCI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	86.99%	72.75%
Newcomers	0%	0%	13.01%	27.25%

Regulars· Jan 14

Johnson & Johnson is acquiring Intra-Cellular Therapies, Inc. for $132 per share, a 39% premium over the company's Friday closing price.
The acquisition is valued at $14.6 billion and marks the first biotech buyout of 2025 for #MAISA, which has seen a 1,290.51% return on its investment in Intra-Cellular Therapies since 2019.
Piper Sandler has downgraded Intra-Cellular Therapies to Neutral from Overweight and raised its price target to $132, a 22% increase from the previous target.

Newcomers· Jan 22

$ITCI's acquisition by JNJ is expected to be smooth, with no major concerns from the HSR review.
The acquisition is anticipated to have a minimal impact on the US market, but could have a significant effect on the company's growth in the coming weeks.
$ITCI and $ONEI's contracts could be a strong growth catalyst, making them a solid long-term play for data-driven solutions.

Generated by AI

News

J&J Q2 Earnings Beat on Darzalex, Tremfya Growth, 2026 Outlook Raised

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about ITCI also mention

#	Name	Attention
1	Axsome Therapeutics IncAXSM	0.01%0
2	KRTX - Karuna Therapeutics, Inc.	——
3	Neurocrine Biosciences, Inc.NBIX	0%new
4	PRTK - Paratek Pharmaceuticals, Inc.	——
5	SAGE - Sage Therapeutics, Inc.	——
6	Acadia Pharmaceuticals Inc.ACAD	0%+0
7	MYOV - Myovant Sciences Ltd.	——
8	MRTX - Mirati Therapeutics, Inc.	——
9	VRNA - Verona Pharma plc	——
10	Mirum Pharmaceuticals, Inc.MIRM	0%0